Jose Luis
Alonso Romero
Asociado Ciencias de la Salud
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicacións en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (2)
2023
-
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041
2022
-
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 6, pp. 1107-1116